A study on the US FDA Regulatory requirements for Stem Cell Based-Products

To thoroughly investigate the regulatory structure implemented by the U.S. Food and Drug Administration (FDA) for products derived from stem cells. As regenerative medicine advances, it is essential to comprehend the FDA’s function in safeguarding the safety, effectiveness, and quality of these therapies.

This research utilizes a thorough method to explore the regulatory requirements set by the U.S. Food and Drug Administration (FDA) for stem cell-derived products. The approach combines qualitative analysis, document review, and case study assessment to evaluate the FDA’s regulatory structure and its influence on the advancement and authorization of regenerative treatments.

This research examine the U.S. FDA’s regulatory framework for stem cell-derived products, including combination products. It clarifies the distinctions between Section 361 and Section 351 HCT/Ps based on criteria like minimal manipulation and homologous use. The article discusses various regulatory pathways, emphasizing the need for Investigational New Drug (IND) and Biologics License Applications (BLA). Additionally, it explores the regulation of stem cell combination products, which may involve devices or drugs. The FDA’s strategy for regulating stem cell-based products demonstrates a dedication to finding a balance between innovation and patient protection. Although important advancements have been achieved in creating explicit guidelines and enforcement strategies, persistent challenges in product characterization, manufacturing processes, and international cooperation need ongoing focus.